Core Viewpoint - The announcement details the plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.'s controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., to supplement the pledge of shares to secure the repayment of bonds and facilitate share exchanges [2][3]. Group 1: Share Pledge Details - As of February 2, 2026, Chuangda Group holds 530,561,726 shares of the company, accounting for 56.38% of the total share capital, with 427,276,426 shares pledged, representing 80.53% of its holdings [2]. - Chuangda Group plans to pledge an additional 1,170,000 shares (0.12% of total share capital, 0.22% of its holdings) to secure the repayment of the second phase of the non-public exchangeable bonds (23 Chuang02EB) [2][3]. - After the completion of this pledge, the total number of pledged shares will increase to 428,446,426, which is 80.75% of Chuangda Group's holdings [3]. Group 2: Financial and Operational Status - Chuangda Group has no controlling persons and has not engaged in any actions that would harm the interests of the listed company, such as non-operational fund occupation or illegal guarantees [7]. - The pledge will not adversely affect the company's main business or operational capabilities, nor will it lead to changes in control [7]. - Chuangda Group's financial health is stable, with no significant litigation or arbitration related to debt issues, and it has sufficient repayment capabilities through operational cash flow and dividends from subsidiaries [11][12].

证券日报网讯 2月3日，珍宝岛（603567）在互动平台回答投资者提问时表示，目前公司生产经营活动 正常开展，不存在网络所述的长期拖欠员工薪资情形。 ...

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-007 黑龙江珍宝岛药业股份有限公司 关于控股股东拟办理非公开发行可交换公司债券 股份补充质押的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至 2026 年 2 月 2 日，黑龙江珍宝岛药业股份有限公司（以下简称"公 司"）控股股东黑龙江创达集团有限公司（以下简称"创达集团"）持有公司股份 530,561,726 股，占公司总股本的 56.38%，其累计质押公司股份数量 427,276,426 股，占所持公司股份数量的 80.53%，无一致行动人。 ● 创达集团拟将持有的 1,170,000 股公司股份（占公司总股本的 0.12%， 占创达集团所持公司股份数量的 0.22%）办理补充质押，用于对债券持有人交换 股份和黑龙江创达集团有限公司-2023 年面向专业投资者非公开发行可交换公 司债券（第二期）（以下简称"23 创 02EB"）本息偿付提供担保。 ● 本次补充质押登记办理完成后，创达集团累计质押公司股份数量为 428, ...

Group 1 - The company stated that its stock price fluctuations are influenced by multiple factors including macroeconomic environment, industry policies, and market sentiment [1] - The company indicated that it is unable to predict stock price trends [1]

Group 1 - The company, Zhenbao Island (603567), reported that as of January 30, 2026, the number of A-share shareholders is 29,044 [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-006 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第一期可 交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码为"137171"，发行规模 9.1 亿元，债券 期限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的 临 2023-019 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 2026 年 2 月 3 日 根据《黑龙江创达集团有限公司 202 ...

Core Viewpoint - Zhenbaodao Pharmaceutical is experiencing robust production growth across its manufacturing bases, driven by strong market demand and a well-structured supply chain that enhances its competitive edge in the industry [1][5]. Group 1: Production and Supply Chain - The company's core formulation production lines are operating at full capacity, with a fully booked production schedule for Q1 2026, particularly for cardiovascular and respiratory products [1]. - Zhenbaodao has established GAP cooperative planting bases in Heilongjiang, Gansu, and Shandong, ensuring consistent quality and cost control of key raw materials through standardized processes and a comprehensive quality traceability system [1]. - The modern logistics system facilitates the efficient transportation of raw materials to the company's processing facilities, where advanced automated production lines operate under centralized control, ensuring precision and efficiency [2]. Group 2: Technological Integration - The integration of SCADA systems allows for real-time monitoring of production processes, ensuring that any deviations from standard values trigger alerts, thus maintaining high consistency across product batches even during full-capacity operations [3]. - The use of MES systems records every batch's process data and quality inspection results, creating a complete digital archive that enhances traceability from raw materials to finished products [2][3]. Group 3: Research and Development - Zhenbaodao is investing in R&D to build a future-oriented product pipeline, focusing on deep development of existing major products and exploring new clinical values [4]. - The company is actively involved in the development of innovative traditional Chinese medicine, biopharmaceuticals, and classic formulations, with recent breakthroughs in antibody-drug conjugates (ADC) for non-Hodgkin lymphoma [4]. Group 4: Competitive Advantage - The company's deep control over key raw materials and standardized production and quality systems provide it with strong operational certainty and profitability resilience amid macroeconomic uncertainties [5]. - Zhenbaodao's comprehensive supply chain model enhances its risk resistance and cost advantages, forming a "moat" that secures market supply and quality safety, laying a foundation for sustainable growth in future industry competition [5].

Core Viewpoint - The performance of A-share pharmaceutical stocks in 2025 shows a mixed outlook, with 283 companies disclosing earnings forecasts, where 160 companies expect profit growth while over 120 companies anticipate profit declines, indicating a significant divergence in the industry [1][3]. Group 1: Profit Growth - Among the 283 pharmaceutical stocks, 160 companies are expected to see a year-on-year increase in net profit, with Sino Medical (688108) leading the pack with a projected increase of over 32 times [1][3]. - Sino Medical forecasts a net profit of 43 million to 50 million yuan for 2025, representing a year-on-year growth of 2,767% to 3,233% [3]. - Other notable companies with significant profit growth include WuXi AppTec, Hanyu Pharmaceutical, and Kangxino, with 65 companies projecting a net profit increase of over 100% [3][4]. Group 2: Profit Decline - Over 120 companies are expected to report a decline in net profit for 2025, with 39 companies facing their first losses since listing, including well-known firms like Zhifei Biological and Zhenbao Island [1][5]. - Zhifei Biological anticipates a net loss of approximately 10.698 billion to 13.726 billion yuan, marking a year-on-year decline of 630% to 780% [6][7]. - The decline in the vaccine sector is attributed to decreased public willingness to vaccinate and increased vaccine hesitancy, leading to significant performance pressure across the industry [7][8]. Group 3: Innovative Drug Companies - Several innovative drug companies are reporting positive trends, with some achieving profitability or significantly reducing losses. For instance, Nocren Pharmaceutical is expected to turn a profit for the first time, projecting a net profit of around 633 million yuan [10]. - Rongchang Biopharmaceutical is also expected to turn a profit, with a projected net profit of approximately 716 million yuan, driven by strong sales of core products [10]. - Companies like Junshi Biosciences and Amgen have not yet achieved profitability but are showing a clear trend of reduced losses, indicating a gradual transition towards commercialization and revenue growth in the innovative drug sector [11].

温永豹：我们启动实施新一轮招商引资"三年行动"，先后引进亿达鸿综合制剂、显东药品加工、德润巨牧鸵鸟养殖深加工等项目，投资1.8亿元建设总占地 面积近500亩的生物医药产业园区，虎林医药企业由5家发展到26家，五年间翻了两番，获得"中国刺五加名城"殊荣；农产品就地加工转换率提升至69.6%。 同时，虎林因地制宜发展新质生产力，中国科学院科学家工作室、中国农业大学教授工作站相继落户，全省首家中药领域院士工作站正式授牌，珍宝岛药业 入选国家技术创新示范企业，虎林生物医药产业集群晋升省级中小企业特色产业集群，科技创新走在全省县域前列。 接下来，虎林将落实省新一轮重点产业链高质量发展行动，全力做强生物医药、绿色食品两大核心产业，重点实施"刺五加+"战略，支持珍宝岛药业、乌苏 里江制药等头部企业增型转产，鼓励全乐制药、亿达鸿药业等成长企业增量扩产，推进中鑫生物低分子精品肝素钠等新建项目早完工、早投产，实体化运 行"借澳出海"公司，加快虎林刺五加地理标志商标和地理标志保护产品申报进程，构建"医药+食品+保健+美妆+日用品"全维度产业生态。力争2030年刺五 加种植总量达到32万亩、加工企业发展到15家、产品突破60种、产业 ...